Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > Therapeutics

Categories

[Search within category]

Mammalian Milk Oligosaccharides as a Potential Prophylactic and Treatment for Viral Respiratory Diseases

Researchers at the University of California, Davis have developed a method of using mammalian milk oligosaccharides as a potential prevention or treatment for viral respiratory diseases - including COVID-19 and influenza.

Reversing COVID-19 associated ARDS and cytokine storm with N-acetylglucosamine

The rapid emergence and spread of a novel coronavirus disease (COVID-19) has caused a global pandemic. Excessive inflammation leading to acute respiratory distress syndrome (ARDS) is the primary driver of mortality in severe COVID-19 cases, and is yet to be addressed by current therapeutics. Researchers at UCI and Mt. Sinai Hospital have therefore developed an anti-inflammatory treatment using N-acetylglucosamine to lower the mortality and need for ventilators in critically ill COVID-19 patients.

Agents for Mitochondrial Biogenesis

Researchers at the University of California, Davis, have developed compounds for the potential prevention and treatment of mitochondrial dysfunction disorders.

Implantable Substance Delivery Devices

This invention describes a method for preparing an implantable device made from biocompatible polymers for sustained delivery of a substance within a body of human or an animal.

Clearance of Senescent Cells by Activation of the Immune Response

Researchers at UCSF have developed a method to selectively clear senescent cells by stimulating an immune response. Accumulation of senescent cells underlies a number of disease conditions and age-related pathologies. Current approaches to clear this cell type use senolytics, these are small-molecules that induce cell death of the senescent cells. Unfortunately, these compounds are not truly specific and affect other non-pathogenic cells. UCSF researchers eliminate these off-target effects by utilizing the body’s immune system to selectively target senescent cells for clearance. They do this by activation and expansion of certain immune cells. Stimulating the immune system to clear these cells is unprecedented in the field and offers a new therapeutic modality to treat senescence associated conditions. The technology has been fully validated in a laboratory setting.

XNA enzymes to Validate and Treat Genetic Diseases

Allelic proteins are often considered undruggable targets, because therapeutics that interfere with these proteins while leaving the wild-type protein unharmed are difficult to come by. Researchers at UCI have developed a xeno-nucleic enzyme (XNAzyme) that offers a solution to this problem by selectively cleaving the mRNA of mutant alleles while leaving the wild-type mRNA unharmed. This novel gene silencing technology offers an efficient, safe, and effective approach to treating genetic diseases.

A Thin Film Nitinol Neurovascular Covered Stent For Small Vessel Aneurysms

UCLA researchers in the Department of Pediatrics have developed a thin and flexible stent that can be implanted in small vessels in the neurovascular system. Normal 0 false false false EN-US ZH-CN X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0in; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi;}

Co-Administration Therapy to Prevent Neurodegeneration and Enhance Neuroprotection

Neurodegenerative diseases are a broad category of illnesses expected to affect 1 in 4 Americans. As they have a variety of underlying mechanisms and pathologies, there are currently no effective methods to prevent or modify disease progression. UCI researchers have developed a potential treatment utilizing a novel combination of two compounds for the abatement of brain inflammation and degeneration.

Combination treatment to rescue age related macular degeneration

Age-related macular degeneration (AMD) is a leading cause of blindness in people over 60 years old. One form, called “dry” AMD is caused by slow cell death of the central retinal pigment epithelial cells (RPE cells), and currently has no treatment. Researchers at UCI have found that by combining a repurposed FDA approved drug in combination with a natural product, they are able to prevent cell death of RPE cells by boosting mitochondria activity.

Novel Prodrug For Anti-Cancer Therapeutic Applications

Inventors at UCI have developed a modified nutrient transporter inhibitor for use as a cancer therapeutic with minimal side effects.

Method to Enhance the Effectiveness of HIV Vaccines

Researchers at the University of California, Davis have developed adjuvants that promotes the efficacy of HIV vaccines.

COMPOSITIONS AND METHODS FOR IDENTIFYING HOST CELL TARGET PROTEINS FOR TREATING RNA VIRUS INFECTIONS

Viral infection is a multistep process involving complex interplay between viral life cycle and host immunity. One defense mechanism that hosts use to protect cells against the virus are nucleic-acid-mediated surveillance systems, such as RNA interference-driven gene silencing and CRISPR-Cas mediated gene editing. Another important stage for host cells to combat virus replication is translational regulation, which is particular important for the life cycle of RNA viruses, such as Hepatitis C virus and Coronavirus.  While efforts to characterize structural features of viral RNA have led to a better understanding of translational regulation, no systematical approaches to identify important host genes for controlling viral translation have been developed and little is known about how to regulate host-virus translational interaction to prevent and treat infections caused by RNA viruses.   UC Berkeley researchers have developed a high-throughput platform using CRISPR-based target interrogation to identify new therapeutics targets or repurposed drug targets for blocking viral RNA translation.  The new kits can also be used to identify important domains within target proteins that are required for regulating (viral RNA translation) and can inform drug design and development for treating RNA viruses.

Therapeutic Approach for Inflammatory Bowel Disease by Targeting Microbial Proteases

Ulcerative colitis (UC), an inflammatory bowel disease (IBD), is characterized by chronic inflammation of the colon, with severity of mucosal inflammation being associated with a higher risk of work disability, hospitalization, colorectal cancer, and colectomy. Non-specific immunosuppressive agents targeting the host, such as steroids, thiopurines, and/or biologics, are used to offset the natural history of disease in patients with moderate-severe inflammation. These therapies are, however, associated with significant risks and often ineffective in adequately managing disease. Genomic technologies have identified associations between microbial dysbiosis, or temporal shifts in composition, and UC severity. While recent efforts extended profiling of microbiota in UC beyond genomics, it remains poorly understood if these shifts are causal or associative in nature, and which mechanisms govern pathogenic roles of the microbiome in UC.

Combination Therapy For Pancreatic Cancer

Pancreatic cancer is an aggressive disease with limited treatment options and a high mortality rate. Pancreatic cancer is the 3rd leading cause of cancer death in the United States; despite some recent advances in systemic therapy, survival remains dismal in large part due to its profound drug resistance and its propensity for early metastasis. Typically, diagnosis of pancreatic cancer occurs only with advanced stages of the disease since there are currently no early markers for detection. Individuals with pancreatic cancer have a poor prognosis due to the late diagnosis, the extent of metastasis, and ineffective treatments. Survival rates are dismal and pancreatic cancer is not typically responsive to radiation and chemotherapy. An alternative approach for the treatment of pancreatic cancer as well as the design of a new class of therapeutics that can be used to treat this devastating disease is an immediate unmet medical need.

Identification of a Novel Target for Inhibition of Leukemia

Rho-family small (~21kDa) GTPases are essential for regulation of numerous cellular functions. There are 20 members of the Rho family in mammals, of which four (Rac1, Rac2, Rac3, RhoG) belong to the Rac subfamily. Each Rac GTPase functions as a molecular switch by cycling between an active GTP-bound form and an inactive GDP-bound form. In addition to their normal cellular functions, Rac GTPases contribute to cancer development as downstream effectors of growth factor receptor signaling and oncogenic mutations in the Ras pathway. Rac GTPases represent attractive targets for therapy in hematologic cancer, however direct targeting of small GTPases has proved difficult and largely ineffective. A thorough understanding of the diverse mechanisms controlling Rac activation in cancer will therefore be essential towards identifying new therapeutic avenues and improving outcomes in patients One insight into the regulation/activation of the Rac GTPases involves examining Ras proteins and their signal transduction pathways since mutations that produce abnormally active Ras proteins are found in 30% of all human cancers. Moreover, after activation, RAS signaling is mediated through interaction with RAS-binding domains or through the domain RAS association (RA), transmitted to downstream effectors. Notably, many downstream effectors are oncogenes or tumor suppressor genes that are mutated or silenced in cancers independently of RAS. Ras proteins are involved in Ras association domain-containing protein 2 (RASSF2) and it has recently been shown that in Acute myeloid leukemia cells with low expression of RASSF2 are more resistant to pharmacological inhibition of Dedicator of cytokinesis protein 2 (DOCK2), a guanine nucleotide exchange factor (GEF). Acute myeloid leukemia cells with high expression of RASSF2 are sensitive to pharmacological inhibition of DOCK2.

Drug Repurposing for Treatment of Fatty Liver Disease and Diabetes

Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat is stored in the liver, though not caused by heavy alcohol use. NAFLD is one of the most common causes of liver disease in the United States. NAFLD it typically asymptomatic but when NAFLD advances, it can result in the development of NASH (Nonalcoholic steatohepatitis) where inflammation and fibrosis are widespread in the liver, resulting in nonalcoholic steatohepatitis and liver cirrhosis. Mechanisms of NAFLD progression are poorly understood. Experts estimate that about 20% of people with NAFLD have NASH. Between 30% and 40% of adults in the United States have NAFLD. About 3% to 12% of adults in the United States have NASH. There are no existing FDA‐approved therapies for nonalcoholic fatty liver disease (NAFLD). NAFLD it typically asymptomatic but it can progress to nonalcoholic steatohepatitis and liver cirrhosis. Mechanisms of NAFLD progression are poorly understood. There are many FDA‐approved therapies for type 2 diabetes, including metformin, insulin, sulfonylureas, Glp‐1 receptor agonists, Dpp‐4 inhibitors, and Sglt2 inhibitors. These drugs work through diverse mechanisms such as increasing insulin secretion (sulfonylureas, Glp‐1 receptor agonists, Dpp‐4 inhibitors), direct insulin replacement (insulin), reducing glucose production by the liver (metformin), and stimulating excretion of glucose into urine (Sglt2 inhibitors).

Modulation of Protein Tyrosine Phosphatase Receptor Type A (PTPRA) to Treat Arthritis

Fibroblast-like synoviocytes (FLS) in the intimal lining of the joint synovium control the composition of the synovial fluid and extracellular matrix (ECM) of the joint lining. In rheumatoid arthritis (RA), FLS become aggressive and invasive, contributing to many aspects of RA pathology. FLS produce matrix metalloproteinases (MMPs) that break down the ECM, directly invade and digest the articular cartilage, promote bone erosion, and promote inflammation through secretion of interleukin 6 (IL-6), chemokines, and other inflammatory mediators. FLS are highly sensitive to the inflammatory environment present in rheumatoid joints. Growth factors, especially platelet-derived growvth factor (PDGF), stimulate FLS invasiveness. Inflammatory cytokines, particularly tumor necrosis factor-alpha (TNF) and interleukin-I (IL-1), enhance FLS aggressiveness, pro-inflammatory features and MMP production. Targeting of molecules that control FLS invasiveness and inflammatory output is being considered an option for development of new therapies for RA.   Many signaling pathways controlling FLS behavior rely upon phosphorylation of proteins on tyrosine residues, which results from the balanced action of protein tyrosine kinases (PTKs) and phosphatases (PTPs). We found that a protein (PTPRA) belonging to a novel and currently untapped class of drug targets is present at high levels in cells lining the joints of RA patients, where we believe it promotes the aggressive behavior of these cells in joint inflammation and destruction.

Bioengineered RNA Molecules for Cancer Therapy

Researchers at the University of California, Davis have developed a method to use biologic RNA molecules for cancer research and therapy.

Bioengineered Let-7c Therapy for HCC Treatment

Researchers at the University of California, Davis have developed a bioengineered, RNA-based treatment for advanced liver cancer and hepatocellular carcinoma (HCC).

Monoclonal Antibodies Specific to Canine PD-1 and PD-L1

Researchers at the University of California, Davis have developed monoclonal antibodies with multiple applications relevant to canine PD-1 and PD-L1.

Novel Mixtures For Synergistic Activation Of M-Channels

Epilepsy is a seizure causing neurological disorder that affects over 50 million people, and it is estimated that half are ineffectively treated with current therapeutic options. Researchers at UCI have isolated components of a plant extract used to treat epilepsy in Africa and discovered that, when combined with an existing epilepsy medication, the mixture greatly decreases epileptic episodes and significantly increases survival rates in rodent models of epilepsy.

Fusion Protein for Treatment of Inflammatory Diseases

Researchers at the University of California, Davis have developed a plant-based, fusion protein for use in the treatment of inflammatory diseases.

Methods of Inhibiting Caspase-6 for the Treatment Of Nash

Nonalcoholic steatohepatitis (NASH), characterized by hepatic steatosis with inflammation and liver damage, has become the leading cause of transplant and liver associated death. Moreover, numerous studies suggest that hepatocellular death is the key event triggering progression to fibrosis and cirrhosis for NASH and perhaps other liver diseases.  In normal liver, hepatocyte apoptosis plays a key role in liver homeostasis, maintaining equilibrium between the loss and replacement of hepatocytes. However, pathological conditions such as viral infection, alcoholic or nonalcoholic steatohepatitis and physical injury, lead to extensive hepatocyte apoptosis and liver damage. While inflammation contributes to the pericellular fibrosis at an early stage, sustained liver damage leads to scarring, bridging fibrosis and subsequent development of cirrhosis. Moreover, hepatocellular death is the major contributor to the pathogenesis of cirrhosis and hepatocellular carcinoma. Therefore, understanding the molecular mechanisms by which hepatocellular death is controlled may lead to new treatments for liver diseases.

Exosome-Mimicking Nanovesicles

Researchers at the University of California, Davis have developed a method of synthesizing stem cell-derived, exosome-mimicking, nanovesicles that have the therapeutic potential to rescue apoptotic neurons in culture.

  • Go to Page: